Adjunctive basal GLP-1-RA therapy in patients after MBS may be a promising treatment choice in weight management in addition to lifestyle changes, not only due to increased GLP-1 signaling, but also to a putative blunting effect on metabolic adaptation that occurs after MBS, increased fat oxidation, and decreased carbohydrate and protein oxidation
Our Ozempic lawyers are consistently investigating the side effects of GLP-1 drugs
Despite the occurrence of some adverse events, these drugs are generally well-tolerated, with gastrointestinal side effects being the most common
Coverage criteria may include: BMI requirements for obesity or overweight with comorbidities
I have so much more energy now, and my confidence is through the roof
If you want to understand how to move past this phase, see How to Break a Weight-Loss Plateau with Tirzepatide (Mounjaro, Zepbound)